文献リスト

1）朝倉英策．播種性血管内凝固症候群(DIC). In: 朝倉英策，編．臨床に直結する血栓止血学．東京: 中外医学社; 2013. p.168-78

2）Asakura H. Classifying types of disseminated intravascular coagulation: Clinical and animal models. J Intensive Care. 2014; 2: 20

3）Gussoni G, Frasson S, La Regina M, et al. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res. 2013; 131: 24-30

4）Walker AJ, Card TR, West J, et al. Incidence of venous thromboembolism in patients with cancer - a cohort study using linked United Kingdom databases. Eur J Cancer. 2013; 49: 1404-13

5）Horsted F, West J, Grainge MJ. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 2012; 9: e1001275

6）Timp JF, Braekkan SK, Versteeg HH, et al. Epidemiology of cancer-associated venous thrombosis. Blood. 2013; 122: 1712-23

7）Pritchard KI, Paterson AH, Paul NA, et al. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. J Clin Oncol. 1996; 14: 2731-7

8）Decousus H, Quere I, Presles E, et al. Superficial venous thrombosis and venous thromboembolism: a large, prospective epidemiologic study. Ann Intern Med. 2010; 152: 218-24

9）van Langevelde K, Lijfering WM, Rosendaal FR, et al. Increased risk of venous thrombosis in persons with clinically diagnosed superficial vein thrombosis: results from the MEGA study. Blood. 2011; 118: 4239-41

10）Prandoni P, Casiglia E, Tikhonoff V, et al. The risk of subsequent cancer and arterial cardiovascular events in patients with superficial vein thrombosis in the legs. Blood. 2011; 118: 4719-22

11）Sørensen HT, Sværke C, Farkas DK, et al. Superficial and deep venous thrombosis, pulmonary embolism and subsequent risk of cancer. Eur J Cancer. 2012; 48: 586-93

12）Davila M, Amirkhosravi A, Coll E, et al. Tissue factor-bearing microparticles derived from tumor cells: impact on coagulation activation. J Thromb Haemost. 2008; 6: 1517-24

13）Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat Cell Biol. 2008; 10: 619-24

14）Khorana AA, Ahrendt SA, Ryan CK, et al. Tissue factor expression, angiogenesis, and thrombosis in pancreatic cancer. Clin Cancer Res. 2007; 13: 2870-5

15）Thaler J, Preusser M, Ay C, et al. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients. Thromb Res. 2013; 131: 162-5

16）Kasthuri RS, Taubman MB, Mackman N. Role of tissue factor in cancer. J Clin Oncol. 2009; 27: 4834-8

17）van den Berg YW, Osanto S, Reitsma PH, et al. The relationship between tissue factor and cancer progression: insights from bench and bedside. Blood. 2012; 119: 924-32

18）Tesselaar ME, Romijn FP, Van Der Linden IK, et al. Microparticle associated tissue factor activity: a link between cancer and thrombosis? J Thromb Haemost. 2007; 5: 520-7

19）Thaler J, Ay C, Mackman N, et al. Microparticleassociated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features. Eur J Clin Invest. 2013; 43: 277-85

20）Hron G, Kollars M, Weber H, et al. Tissue factorpositive microparticles: cellular origin and association with coagulation activation in patients with colorectal cancer. Thromb Haemost. 2007; 97: 119-23

21）Haubold K, Rink M, Spath B, et al. Tissue factor procoagulant activity of plasma microparticles is increased in patients with early-stage prostate cancer. Thromb Haemost. 2009; 101: 1147-55

22）Sartori MT, Della Puppa A, Ballin A, et al. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol. 2011; 104: 225-31

23）Sartori MT, Della Puppa A, Ballin A, et al. Circulating microparticles of glial origin and tissue factor bearing in high-grade glioma: a potential prothrombotic role. Thromb Haemost. 2013; 110: 378-85

24）Del Conde I, Bharwani LD, Dietzen DJ,et al. Microvesicle-associated tissue factor and Trousseauʼs syndrome. J Thromb Haemost. 2007; 5: 70-4

25）Boles JC, Williams JC, Hollingsworth RM, et al. Anthracycline treatment of the human monocytic leukemia cell line THP-1 increases phosphatidylserine exposure and tissue factor activity. Thromb Res. 2012; 129: 197-203

26）Lechner D, Kollars M, Gleiss A, et al. Chemotherapy-induced thrombin generation via procoagulant endothelial microparticles is independent of tissue factor activity. J Thromb Haemost. 2007; 5: 2445-52

27）Fu Y, Zhou J, Li H, et al. Daunorubicin induces procoagulant activity of cultured endothelial cells through phosphatidylserine exposure and microparticles release. Thromb Haemost. 2010; 104: 1235-41

28）Zhou J, Zheng Y, Shi J, et al. Daunorubicin induces procoagulant response through phosphatidylserine exposure in red blood cells. Thromb Res. 2010; 125: 178-83

29）Zhou J, Shi J, Hou J, et al. Phosphatidylserine exposure and procoagulant activity in acute promyelocytic leukemia. J Thromb Haemost. 2010; 8: 773-82

30）Zwicker JI, Liebman HA, Neuberg D, et al. Tumor derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009; 15: 6830-40

31）Tesselaar ME, Romijn FP, van der Linden IK, et al. Microparticle-associated tissue factor activity in cancer patients with and without thrombosis. J Thromb Haemost. 2009; 7: 1421-3

32）Manly DA, Wang J, Glover SL, et al. Increased microparticle tissue factor activity in cancer patients with venous thromboembolism. Thromb Res. 2010; 125: 511-2

33）Campello E, Spiezia L, Radu CM, et al. Endothelial, platelet, and tissue factor-bearing microparticles in cancer patients with and without venous thromboembolism. Thromb Res. 2011; 127: 473-7

34）Khorana AA, Francis CW, Menzies KE, et al. Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer. J Thromb Haemost. 2008; 6: 1983-5

35）Auwerda JJ, Yuana Y, Osanto S, et al. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma. Thromb Haemost. 2011; 105: 14-20

36）van Doormaal F, Kleinjan A, Berckmans RJ, et al. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study. Thromb Haemost. 2012; 108: 160-5

37）Thaler J, Ay C, Mackman N, et al. Microparticleassociated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patients. J Thromb Haemost. 2012; 10: 1363-70

38）Bharthuar A, Khorana AA, Hutson A, et al. Circulating microparticle tissue factor, thromboembolism and survival in pancreaticobiliary cancers. Thromb Res. 2013; 132: 180-4

39）Thaler J, Pabinger I, Sperr WR, et al. Clinical evidence for a link between microparticle-associated tissue factor activity and overt disseminated intravascular coagulation in patients with acute myelocytic leukemia. Thromb Res. 2014; 133: 303-5

40）Geddings JE, Mackman N. Tumor-derived tissue factor-positive microparticles and venous thrombosis in cancer patients. Blood. 2013; 122: 1873-80

41）Khorana AA, Kuderer NM, Culakova E,et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111: 4902-7

42）Connolly GC, Khorana AA, Kuderer NM, et al. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. Thromb Res. 2010; 126: 113-8

43）Trujillo-Santos J, Di Micco P, Iannuzzo M, et al. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008; 100: 905-11

44）Zakai NA, Wright J, Cushman M. Risk factors for venous thrombosis in medical inpatients: validation of a thrombosis risk score. J Thromb Haemost. 2004; 2: 2156-61

45）Khorana AA, Francis CW, Culakova E, et al. Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer. 2005; 104: 2822-9

46）Blann AD, Noteboom WM, Rosendaal FR. Increased soluble P-selectin levels following deep venous thrombosis: cause or effect? Br J Haematol. 2000; 108: 191-3

47）Gremmel T, Ay C, Seidinger D, Pabinger I, et al. Soluble P-selectin, D-dimer, and high-sensitivity C-reactive protein after acute deep vein thrombosis of the lower limb. J Vasc Surg. 2011; 54(6 Suppl): 48S-55S

48）Ay C, Jungbauer LV, Sailer T, et al. High concentrations of soluble P-selectin are associated with risk of venous thromboembolism and the P-selectin Thr715 variant. Clin Chem. 2007; 53: 1235-43

49）Ay C, Simanek R, Vormittag R, et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood. 2008; 112: 2703-8

50）Kodama J, Seki N, Masahiro S, Kusumoto T, et al. D-dimer level as a risk factor for postoperative venous thromboembolism in Japanese women with gynecologic cancer. Ann Oncol. 2010; 21: 1651-6

51）Ferroni P, Martini F, Portarena I, et al. Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients. Clin Lung Cancer. 2012; 13: 482-7

52）Ay C, Vormittag R, Dunkler D, et al. Predictive value of D-dimer levels for venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) [abstract]. Blood. 2008; 112. Abstract 3824

53）Ay C, Dunkler D, Marosi C, et al. Prediction of venous thromboembolism in cancer patients. Blood. 2010; 116: 5377-82

54）Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood. 2013; 122: 2011-8

55）Ay C, Vormittag R, Dunkler D, et al. D-dimer and prothrombin fragment 1+2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol. 2009; 27: 4124-9

56）Thaler J, Ay C, Pabinger I. Venous thromboembolism in cancer patients - risk scores and recent randomised controlled trials. Thromb Haemost. 2012; 108: 1042-8

57）Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol. 2011; 29: 573-82

58）Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005; 23: 2224-32

59）Harrison CN, Campbell PJ, Buck G, et al; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005; 353: 33-45

60）Gisslinger H, Gotic M, Holowiecki J, et al; ANAHYDRET Study Group. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013; 121: 1720-8

61）Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011; 117: 5857-9

62）Smalberg JH, Arends LR, Valla DC, et al. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012; 120: 4921-8

63）Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005; 128: 275-90

64）Barbui T, Carobbio A, Cervantes F, et al. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood. 2010; 115: 778-82

65）Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol. 2007; 35: 702-11

66）Maugeri N, Malato S, Femia EA, et al. Clearance of circulating activated platelets in polycythemia vera and essential thrombocythemia. Blood. 2011; 118: 3359-66

67）Jensen MK, de Nully Brown P, Lund BV, et al. Increased platelet activation and abnormal membrane glycoprotein content and redistribution in myeloproliferative disorders. Br J Haematol. 2000; 110: 116-24

68）Panova-Noeva M, Marchetti M, Buoro S, et al. JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients. Blood. 2011; 118: 2599-601

69）Adams BD, Baker R, Lopez JA, et al. Myeloproliferative disorders and the hyperviscosity syndrome. Hematol Oncol Clin North Am. 2010; 24: 585-602

70）Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood. 2013; 122: 2176-84

71）De Grandis M, Cambot M, Wautier MP, et al. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoRindependent Rap1/Akt pathway. Blood. 2013; 121: 658-65

72）Marchetti M, Falanga A. Leukocytosis, JAK2V617F mutation, and hemostasis in myeloproliferative disorders. Pathophysiol Haemost Thromb. 2008; 36: 148-59

73）Trelinski J, Wierzbowska A, Krawczynska A, et al. Plasma levels of angiogenic factors and circulating endothelial cells in essential thrombocythemia: correlation with cytoreductive therapy and JAK2-V617F mutational status. Leuk Lymphoma. 2010; 51: 1727-33

74）Belotti A, Elli E, Speranza T, et al. Circulating endothelial cells and endothelial activation in essential thrombocythemia: results from CD1461 immunomagnetic enrichment-flow cytometry and soluble E-selectin detection. Am J Hematol. 2012; 87: 319-20

75）Marchetti M, Castoldi E, Spronk HM, et al. Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera. Blood. 2008; 112: 4061-8

76）Dienava-Verdoold I, Marchetti MR, te Boome LC, et al. Platelet-mediated proteolytic down regulation of the anticoagulant activity of protein S in individuals with haematological malignancies. Thromb Haemost. 2012; 107: 468-76

77）Marchioli R, Finazzi G, Specchia G, et al; CYTOPV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013; 368: 22-33

78）Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012; 120: 1409-11

79）Barbui T, Barosi G, Birgegard G, et al; European LeukemiaNet. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011; 29: 761-70

80）Barbui T, Carobbio A, Rambaldi A, et al. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood. 2009; 114: 759-63

81）Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET thrombosis). Blood. 2012; 120: 5128-33

82）Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004; 350: 114-24

83）Alvarez-Larran A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010; 116: 1205-10

84）Pascale S, Petrucci G, Dragani A, et al. Aspirininsensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. Blood. 2012; 119: 3595-603

85）Tefferi A, Barbui T. Personalized management of essential thrombocythemia-application of recent evidence to clinical practice. Leukemia. 2013; 27: 1617-20

86）Akl EA, Kahale L, Neumann I, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014; 6: CD006649

87）Lyman GH, Khorana AA, Kuderer NM, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013; 31: 2189-204

88）Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100: 3484-8

89）Akl EA, Kahale L, Barba M, et al. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev. 2014; 7: CD006650

90）Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med. 2004; 164: 1653-61

91）den Exter PL, Hooijer J, Dekkers OM, et al. Risk of recurrent venous thromboembolism and mortality in patients with cancer incidentally diagnosed with pulmonary embolism: a comparison with symptomatic patients. J Clin Oncol. 2011; 29: 2405-9

92）Menapace LA, Peterson DR, Berry A, et al. Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost. 2011; 106: 371-8

93）Sun JM, Kim TS, Lee J, et al. Unsuspected pulmonary emboli in lung cancer patients: the impact on survival and the significance of anticoagulation therapy. Lung Cancer. 2010; 69: 330-6

94）Munter G, Hershko C. Increased warfarin sensitivity as an early manifestation of occult prostate cancer with chronic disseminated intravascular coagulation. Acta Haematol. 2001; 105: 97-9

95）Hayashi T, Nakagawa N, Asakura H, et al. Rivaroxaban in a patient with disseminated intravascular coagulation associated with an aortic aneurysm: a case report. Ann Intern Med. 2014; 161: 158-9

96）朝倉英策．新規経口抗凝固薬(NOAC). In: 朝倉英策，編．臨床に直結する血栓止血学．東京: 中外医学社; 2013. p.321-9

97）Lee AY1, Peterson EA. Treatment of cancer-associated thrombosis. Blood. 2013; 122: 2310-7

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp